文献速递膀胱癌与上尿路尿路上皮癌

吸烟暴露与新辅助化疗反应及膀胱根治性切除术后生存结局的系统综述与荟萃分析

Association between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes following Radical Cystectomy: Systematic Review and Meta-Analysis.
PubMed 文献 · J Urol · 2020-02-27

该系统综述与荟萃分析检索截至2019年4月的文献,纳入17项观察性研究共13,777例膀胱癌根治性膀胱切除术患者,评估吸烟状态对生存结局的影响。结果显示,活跃吸烟者总体死亡、癌症特异死亡和膀胱癌复发风险均显著升高;仅接受新辅助化疗后手术的患者中,非吸烟/从不吸烟者新辅助化疗完全缓解率更优。

要点

  • 活跃吸烟者根治性膀胱切除术后总体死亡风险升高(HR 1.21)。
  • 活跃吸烟者癌症特异死亡和膀胱癌复发风险均升高(HR 1.24)。
  • 非/从不吸烟者新辅助化疗完全缓解率更优(HR 0.47)。

核心结论

  • 吸烟状态与较低的新辅助化疗反应率及根治性膀胱切除术后更高的总体死亡、癌症特异死亡和膀胱癌复发风险相关。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、MEDLINE、Embase和Cochrane Library截至2019年4月的原始文章。
  • 纳入17项观察性研究,共13,777例接受根治性膀胱切除术的膀胱癌患者。
  • 主要终点为新辅助化疗反应、总体死亡、癌症特异死亡和无复发生存。
  • 定量分析纳入多变量风险比及95%CI,并进行敏感性分析和非随机研究偏倚风险评估。

主要发现

  • 活跃吸烟者总体死亡风险增加(HR 1.21,95%CI 1.08-1.36;p=0.001,I2=0%)。
  • 活跃吸烟者癌症特异死亡风险增加(HR 1.24,95%CI 1.13-1.36;p<0.00001,I2=0%)。
  • 活跃吸烟者膀胱癌复发风险增加(HR 1.24,95%CI 1.12-1.38;p<0.0001,I2=3%)。
  • 仅评估接受新辅助化疗后根治性膀胱切除术患者的敏感性分析显示,非/从不吸烟者新辅助化疗完全缓解率更优(HR 0.47,95%CI 0.29-0.75;p=0.001,I2=0%)。

临床怎么用

  • 术前应针对吸烟状态进行适当宣教咨询。
  • 对吸烟患者可考虑 tightened followup 以改善长期生存结局。

局限性

  • 纳入研究均为观察性研究,已完成非随机研究的偏倚风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Studies exploring the association of cigarette smoking and long-term survival outcomes following radical cystectomy have yielded mixed results. We performed a systematic review and meta-analysis to investigate the impact of tobacco smoking exposure, duration, intensity and cessation on response to neoadjuvant chemotherapy and long-term survival outcomes in patients undergoing radical cystectomy for bladder cancer. MATERIALS AND METHODS: We systematically searched PubMed®, MEDLINE®, Embase® and Cochrane® Library databases for original articles published before April 2019. Primary end points were neoadjuvant chemotherapy response, overall and cancer specific mortality, and recurrence-free survival after radical cystectomy. Observational studies reporting Cox proportional hazards regression or logistic regression analysis were independently screened. Available multivariable hazard ratios and corresponding 95% CIs were included in the quantitative analysis. Sensitivity analyses were performed as appropriate. A risk of bias assessment was completed for nonrandomized studies. RESULTS: Our electronic search identified a total of 649 articles. After a detailed review we selected 17 studies that addressed the impact of smoking status on survival outcomes in 13,777 patients after radical cystectomy for bladder cancer. Pooled meta-analysis revealed that active smokers have an increased risk of overall mortality (HR 1.21, 95% CI 1.08-1.36; p=0.001, I2=0%), cancer specific mortality (HR 1.24, 95% CI 1.13-1.36; p <0.00001, I2=0%) and bladder cancer recurrence (HR 1.24, 95% CI 1.12-1.38; p <0.0001, I2=3%). Sensitivity analyses evaluating only patients who underwent neoadjuvant chemotherapy followed by radical cystectomy showed an advantage of non/never smokers in terms of neoadjuvant chemotherapy complete response rate (HR 0.47, 95% CI 0.29-0.75; p=0.001, I2=0%). CONCLUSIONS: Smoking status is associated with lower neoadjuvant chemotherapy response rates and higher overall and cancer specific mortality as well as bladder cancer recurrence after radical cystectomy. Appropriate preoperative counseling, together with tightened followup, may have a pivotal role in improving the smoking-related long-term survival outcomes in patients with bladder cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Cacciamani GE, Ghodoussipour S, Mari A, et al. Association between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes following Radical Cystectomy: Systematic Review and Meta-Analysis. J Urol. 2020. PMID: 32105187. doi:10.1097/JU.0000000000000813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。